Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by hmmmmmmmmon Nov 12, 2021 2:10pm
182 Views
Post# 34120822

Do they even have 35 DIMI machines?

Do they even have 35 DIMI machines?Spectral registered it's Usability Trial over 6 mos ago.

They announced the trial would start 4 months later in the 3rd quarter.

Spectral hired Cromsource to manage the DIMI trial more than 5 months ago.


Cromsource said: "While our experience in managing medical device trials is important to Dialco, our flexibility and adaptability, particularly during a global pandemic, make us the ideal partner."

There are over 550,000 dialysis patients in over 7,000 clinics in the US.


So how do we make sense of them being 6 months late in starting the trial?

Can they really not find a clinic or two and 35 patients?

It's hard to believe.


Could it be that they simply don't have 35 DIMI machines?

Asking for Occam.
<< Previous
Bullboard Posts
Next >>